Page last updated: 2024-12-05
Methyl 2-benzoylbenzoate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
methyl 2-benzoylbenzoate: a photoinitiator; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 11816 |
| CHEMBL ID | 3629239 |
| CHEBI ID | 191129 |
| SCHEMBL ID | 28000 |
Synonyms (47)
| Synonym |
|---|
| AC-16418 |
| methyl 2-(phenylcarbonyl)benzoate |
| STK731405 |
| einecs 210-112-3 |
| nsc 3797 |
| ai3-00516 |
| methyl 2-benzoylbenzoate |
| nsc3797 |
| 2-benzoylbenzoic acid, methyl ester |
| nsc-3797 |
| o-(methoxycarbonyl)benzophenone |
| 606-28-0 |
| methyl o-benzoylbenzoate |
| benzoic acid, 2-benzoyl-, methyl ester |
| benzoic acid, o-benzoyl-, methyl ester |
| TIMTEC1_000331 |
| methyl-2-benzoylbenzoate, 97% |
| NCGC00175229-01 |
| inchi=1/c15h12o3/c1-18-15(17)13-10-6-5-9-12(13)14(16)11-7-3-2-4-8-11/h2-10h,1h |
| HMS1534P01 |
| methyl benzophenone-2-carboxylate |
| benzophenone-2-carboxylic acid methyl ester |
| 2-benzoylbenzoic acid methyl ester |
| B1231 |
| bdbm50129069 |
| chembl3629239 , |
| BRD-K82275274-001-01-1 |
| AKOS003827563 |
| CHEBI:191129 |
| o-benzoyl benzomethoxycarbonyl(obm) |
| methyl-2-benzoylbenzoate |
| FT-0632520 |
| SCHEMBL28000 |
| DTXSID2060549 , |
| 2-benzoyl benzoic acid methyl ester |
| o-benzoylbenzoic acid methyl ester |
| o-benzoyl benzoic acid, methyl ester |
| W-105240 |
| benzoic acid, benzoyl-, methyl ester |
| mfcd00017187 |
| Z19663893 |
| AS-12023 |
| 2-benzoyl benzoic acid methyl ester;benzoic acid, 2-benzoyl-, methyl ester;methyl 2-benzoylbenzoate;methyl 2-(phenylcarbonyl)benzoate;benzoic acid, o-benzoyl-, methyl ester;2-benzoyl benzoic acid methyl ester benzoic acid, 2-benzoyl-, methyl ester methyl |
| 2-benzoylbenzoic acid-methyl ester |
| CS-W010289 |
| F87465 |
| XUP7S9NT59 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| benzophenones | Any aromatic ketone in which the carbonyl group is bonded to 2 phenyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-lactamase class B VIM-2 | Pseudomonas aeruginosa | IC50 (µMol) | 3,000.0000 | 1.6600 | 4.3867 | 8.0000 | AID1254039 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1254039 | Inhibition of Pseudomonas aeruginosa 301-5473 metallo-beta-lactamase VIM-2 expressed in Escherichia coli BL21(DE3) using nitrocefin as substrate preincubated for 5 mins followed by substrate addition measured every 17 secs for 20 mins by microplate reader | 2015 | Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21 | Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 27.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (27.60) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||